Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Biocon gets JDRF...

    Biocon gets JDRF support for global study on diabetes molecule

    Written by Ruby Khatun Khatun Published On 2017-09-07T10:02:00+05:30  |  Updated On 18 Aug 2021 3:42 PM IST

    New Delhi: Biotechnology major Biocon on Thursday said it has received financial support from the US-based JDRF for a global clinical study of its oral insulin drug candidate Insulin Tregopil.


    The study will be focussed on patients with type 1 diabetes (T1D), an autoimmune condition in which the body's immune system is activated to destroy insulin producing cells in the pancreas.


    "With this proposed clinical study, we hope to build on the extremely promising data that we have generated so far through previous human trials with Tregopil," Biocon CMD Kiran Mazumdar-Shaw said in a statement.


    JDRF is a leading global organization funding T1D research and advocacy worldwide.


    Biocon, however, did not share details about the quantum of financial support it will receive from JDRF.


    Tregopil, a first-in-class oral insulin molecule being developed by Biocon, is one of the most advanced programs in the global oral insulin space.


    The fast-acting oral insulin could improve postprandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management.


    "We believe Tregopil can make a significant difference to the diabetes management paradigm for both type 1 and type 2 diabetes and welcome JDRF's support in advancing this unique oral insulin molecule through the clinic for type 1 diabetes," Mazumdar-Shaw said.


    The Bengaluru-based firm proposes to conduct an open label study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of multiple ascending doses of Tregopil.


    It also plans to compare the PK, PD, and safety of the optimal dose regimen of Tregopil with therapeutic doses of Insulin Aspart in individuals with T1D.


    JDRF through its Industry Discovery and Development Partnership (IDDP) program provides financial support to accelerate breakthrough research in T1D management.


    Globally, around 422 million adults were living with diabetes in 2014.

    autoimmune conditionsBiocondiabetesdiabetes moleculefinancial supportglobal studyIndustry Discovery and Development PartnershipinsulinJDRFKiran Mazumdar Shaworal insulin drugsupportTregopiltype 1 diabetes
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok